Antigen slumps after FDA puts Oncophage trials on hold

NEW YORK (CBS.MW) -- Shares of Antigenics
AGEN, +2.29%
slumped $1.77 or 13 percent, to $12.28 after the company said the U.S. Food and Drug Administration put its Phase III trials of its cancer vaccine, Onchophage, on hold pending additional product characterization information. The FDA said the request for more information was not a safety issue, and patients currently enrolled in the trials could proceed with vaccination.

Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.